Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs will be updated July 1, 2025:

Effective Aug. 1, 2025:

• ATTR Amyloidosis
• Casgevy
• Colony Stimulating Factors
• Denosumab Osteoporosis
• GLP-1
• Iron Replacement
• Izervay
• Joenja
• Journavx
• Jynarque
• Lenmeldy
• Leqembi
• Leqvio
• Lyfgenia
• Lysosomal Storage Disorder
• PCSK9 Inhibitors
• PAH
• Ryoncil
• Skyclarys
• Skysona
• Vasomotor Symptoms
• Interleukin (IL-1) Inhibitors

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website. 

If you have any questions please contact your BCBSKS provider relations representative.